PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Release Date: June 30, 2025

Expiration Date: June 30, 2026

Activity Overview

The PER Postgame^™ is an online, on-demand video program that brings together renowned experts in the treatment of IgA nephropathy (IgAN). In this educational program, these experts review the screening and diagnosis of IgAN utilizing a multidisciplinary approach and delve into current and emerging therapies that have been developed based on advancements in knowledge regarding the pathogenesis of IgAN. A case study will be presented, allowing the experts to share their perspectives on treatment and best practices.

Target Audience

This educational activity is directed toward nephrology nurses. Nephrologists and other HCPs involved in the management of patients with IgAN will also find it useful.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Discuss the most recent updates on the pathophysiology and pathogenesis of IgAN
• Apply strategies to evaluate patients with IgAN
• Analyze recent efficacy and safety trial data on new and emerging treatments for IgAN
• Summarize guideline recommendations for the individualized treatment of patients with IgAN

Editor's Note:

On August 27, 2025, the FDA modified the Risk Evaluation and Mitigation Strategies (REMS) program for the use of sparsentan in the treatment of IgA nephropathy due to the risk of hepatotoxicity. The update reduces the frequency of liver function monitoring to every 3 months from the onset of treatment with sparsentan and removes the embryo-fetal toxicity (EFT) monitoring requirement from the REMS.